{"hands_on_practices": [{"introduction": "Understanding how quickly a drug is metabolized is central to pharmacology. This process is often described by two key parameters: the maximum rate ($V_{max}$) and the Michaelis constant ($K_m$). This problem challenges you to use these values to calculate the intrinsic clearance ($CL_{int}$), a powerful measure of metabolic efficiency, and to predict the reaction rate at a specific drug concentration, reinforcing your grasp of fundamental enzyme kinetics. [@problem_id:4548601]", "problem": "A neutral, lipophilic probe substrate undergoing a cytochrome P450-mediated Phase I oxidation in pooled human liver microsomes is characterized under initial-rate conditions at $37\\,^{\\circ}\\mathrm{C}$. The microsomal protein-normalized maximal velocity is measured as $V_{max} = 200$ pmol min$^{-1}$ mg$^{-1}$, and the Michaelis constant is $K_{m} = 10$ $\\mu$M. Assume classical single-enzyme Michaelis–Menten behavior under steady-state conditions, negligible nonspecific binding, and that measurements are made in the linear initial-rate regime. Using only standard enzyme kinetic definitions, determine:\n- the intrinsic clearance $CL_{int}$, defined as the limiting slope of the velocity–substrate concentration relationship as substrate concentration approaches zero, and\n- the initial metabolic rate $v$ at substrate concentration $S = 5$ $\\mu$M.\n\nExpress $CL_{int}$ in $\\mu$L min$^{-1}$ mg$^{-1}$ protein and $v$ in pmol min$^{-1}$ mg$^{-1}$ protein. Round both requested quantities to three significant figures. Report your answers ordered as $(CL_{int}, v)$.", "solution": "The problem statement is first subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\n- **System**: A neutral, lipophilic probe substrate undergoing a cytochrome P450-mediated Phase I oxidation in pooled human liver microsomes.\n- **Conditions**: Initial-rate conditions at a temperature of $37\\,^{\\circ}\\mathrm{C}$.\n- **Kinetic Parameters**:\n  - Maximal velocity, $V_{max} = 200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$.\n  - Michaelis constant, $K_{m} = 10 \\text{ } \\mu\\text{M}$.\n- **Assumptions**:\n  - Classical single-enzyme Michaelis–Menten behavior.\n  - Steady-state conditions.\n  - Negligible nonspecific binding.\n  - Measurements are made in the linear initial-rate regime.\n- **Definitions and Tasks**:\n  1. Determine the intrinsic clearance, $CL_{int}$, defined as \"the limiting slope of the velocity–substrate concentration relationship as substrate concentration approaches zero\".\n  2. Determine the initial metabolic rate, $v$, at a substrate concentration of $S = 5 \\text{ } \\mu\\text{M}$.\n- **Output Requirements**:\n  - Express $CL_{int}$ in units of $\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$ protein.\n  - Express $v$ in units of pmol min$^{-1}$ mg$^{-1}$ protein.\n  - Round both quantities to three significant figures.\n  - Report the answers in the order $(CL_{int}, v)$.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Groundedness**: The problem is firmly grounded in the principles of enzyme kinetics and pharmacology. The scenario, involving cytochrome P450 enzymes in human liver microsomes, and the kinetic parameters ($V_{max}$, $K_m$) are standard and realistic for in vitro drug metabolism studies.\n- **Well-Posedness**: The problem is well-posed. It provides all necessary data and clear definitions based on the Michaelis–Menten model to uniquely determine the requested quantities.\n- **Objectivity**: The problem is stated using precise, objective, and quantitative language, devoid of any subjectivity or bias.\n- **Completeness and Consistency**: The problem is self-contained and internally consistent. The assumptions provided are standard for simplifying the system to a solvable model.\n- **Realism**: The values for $V_{max}$ and $K_m$ are entirely plausible for a P450-mediated reaction.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, well-posed, and complete. It is therefore deemed **valid**. A solution will be derived.\n\nThe kinetics of the reaction are described by the Michaelis–Menten equation, which relates the initial reaction velocity $v$ to the substrate concentration $S$:\n$$v = \\frac{V_{max} S}{K_m + S}$$\nwhere $V_{max}$ is the maximal velocity and $K_m$ is the Michaelis constant.\n\n**1. Determination of Intrinsic Clearance ($CL_{int}$)**\n\nThe problem defines intrinsic clearance, $CL_{int}$, as the limiting slope of the velocity–substrate concentration relationship as $S$ approaches zero. This can be interpreted as the initial slope of the $v$ versus $S$ curve, which is the derivative $\\frac{dv}{dS}$ evaluated at $S=0$. Let us compute this derivative using the quotient rule:\n$$\\frac{dv}{dS} = \\frac{d}{dS}\\left(\\frac{V_{max} S}{K_m + S}\\right) = \\frac{V_{max}(K_m + S) - (V_{max} S)(1)}{(K_m + S)^2} = \\frac{V_{max} K_m}{(K_m + S)^2}$$\nTaking the limit as $S \\to 0$:\n$$CL_{int} = \\lim_{S \\to 0} \\frac{dv}{dS} = \\frac{V_{max} K_m}{(K_m + 0)^2} = \\frac{V_{max}}{K_m}$$\nAlternatively, clearance is defined as the rate of elimination divided by the concentration, $v/S$. Intrinsic clearance is the limit of this ratio at low substrate concentrations:\n$$CL_{int} = \\lim_{S \\to 0} \\frac{v}{S} = \\lim_{S \\to 0} \\frac{V_{max} S}{S(K_m + S)} = \\lim_{S \\to 0} \\frac{V_{max}}{K_m + S} = \\frac{V_{max}}{K_m}$$\nBoth interpretations yield the same, standard result.\n\nThe given values are $V_{max} = 200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$ and $K_m = 10 \\text{ } \\mu\\text{M}$. To obtain $CL_{int}$ in the required units of $\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$, we must perform a unit conversion for $K_m$.\n$$1 \\text{ M} = 1 \\text{ mol L}^{-1}$$\n$$K_m = 10 \\text{ } \\mu\\text{M} = 10 \\frac{\\mu\\text{mol}}{\\text{L}}$$\nWe convert the units to match those in $V_{max}$ (picomoles) and the desired output (microliters).\n$$1 \\text{ }\\mu\\text{mol} = 10^6 \\text{ pmol}$$\n$$1 \\text{ L} = 10^6 \\text{ }\\mu\\text{L}$$\nTherefore, the concentration unit conversion is:\n$$1 \\frac{\\mu\\text{mol}}{\\text{L}} = \\frac{10^6 \\text{ pmol}}{10^6 \\text{ }\\mu\\text{L}} = 1 \\frac{\\text{pmol}}{\\mu\\text{L}}$$\nSo, $K_m = 10 \\text{ pmol } \\mu\\text{L}^{-1}$.\n\nNow we can calculate $CL_{int}$:\n$$CL_{int} = \\frac{V_{max}}{K_m} = \\frac{200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}}{10 \\text{ pmol } \\mu\\text{L}^{-1}} = 20 \\text{ }\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$$\nThe problem requires rounding to three significant figures. Thus, $CL_{int} = 20.0 \\text{ }\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$.\n\n**2. Determination of Initial Metabolic Rate ($v$)**\n\nThe initial metabolic rate $v$ at a substrate concentration of $S = 5 \\text{ } \\mu\\text{M}$ is calculated by direct substitution into the Michaelis–Menten equation.\nThe parameters are:\n- $V_{max} = 200 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$\n- $K_m = 10 \\text{ } \\mu\\text{M}$\n- $S = 5 \\text{ } \\mu\\text{M}$\n\nSince $K_m$ and $S$ have the same units ($\\mu\\text{M}$), they can be used directly in the equation, and the resulting units for $v$ will be the units of $V_{max}$.\n$$v = \\frac{V_{max} S}{K_m + S} = \\frac{(200 \\text{ pmol min}^{-1} \\text{ mg}^{-1})(5 \\text{ }\\mu\\text{M})}{10 \\text{ }\\mu\\text{M} + 5 \\text{ }\\mu\\text{M}}$$\n$$v = \\frac{200 \\times 5}{10 + 5} \\text{ pmol min}^{-1} \\text{ mg}^{-1} = \\frac{1000}{15} \\text{ pmol min}^{-1} \\text{ mg}^{-1}$$\n$$v = \\frac{200}{3} \\text{ pmol min}^{-1} \\text{ mg}^{-1} \\approx 66.666... \\text{ pmol min}^{-1} \\text{ mg}^{-1}$$\nRounding to three significant figures, we get:\n$$v = 66.7 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$$\n\nThe final results, ordered as specified, are $CL_{int} = 20.0 \\text{ }\\mu\\text{L min}^{-1} \\text{ mg}^{-1}$ and $v = 66.7 \\text{ pmol min}^{-1} \\text{ mg}^{-1}$.", "answer": "$$\n\\boxed{\\begin{pmatrix} 20.0 & 66.7 \\end{pmatrix}}\n$$", "id": "4548601"}, {"introduction": "While kinetic parameters tell us how fast a drug is metabolized, the drug's chemical structure dictates *where* the metabolism occurs. This exercise asks you to act like a medicinal chemist, analyzing a molecule with multiple potential reaction sites and predicting the most likely point of initial oxidative attack by cytochrome P450 enzymes. By comparing factors like bond dissociation energy and electronic activation, you will practice applying fundamental chemical principles to foresee a drug's metabolic fate. [@problem_id:4548577]", "problem": "A lipophilic, overall neutral small-molecule drug contains a single tertiary aliphatic amine (bearing at least one $\\alpha$-carbon with C–H bonds) and elsewhere on the scaffold a remote isopropyl group attached to a saturated, non-benzylic, non-allylic carbon. The drug is incubated with human liver microsomes. Using first principles for Phase I functionalization reactions, predict the most likely first transformation and justify your choice by comparing bond dissociation energies and electronic factors at the candidate sites. Select the single best answer.\n\nA. Cytochrome P450 (CYP)-mediated oxidative N-dealkylation initiated by hydrogen abstraction at the carbon $\\alpha$ to the tertiary amine, proceeding through a carbinolamine that fragments to a secondary amine and a carbonyl compound.\n\nB. Flavin-containing monooxygenase (FMO)-mediated N-oxidation of the tertiary amine to the corresponding amine N-oxide as the dominant initial pathway.\n\nC. Cytochrome P450 (CYP)-mediated hydroxylation at the methine carbon of the isopropyl group (the tertiary C–H) to yield a tertiary alcohol.\n\nD. Direct hydrolytic cleavage of a C–N bond of the tertiary amine to remove an alkyl group without prior oxidation.\n\nE. Alcohol dehydrogenase-mediated oxidation of the isopropyl substituent to a ketone as the initiating step.", "solution": "The user wants me to solve the problem.\n**Step 1: Extract Givens**\n- Substrate: A lipophilic, overall neutral small-molecule drug.\n- Functional Group 1: A single tertiary aliphatic amine.\n- Condition for Functional Group 1: The amine bears at least one $\\alpha$-carbon with C–H bonds.\n- Functional Group 2: A remote isopropyl group.\n- Condition for Functional Group 2: Attached to a saturated, non-benzylic, non-allylic carbon.\n- Reaction Conditions: Incubation with human liver microsomes.\n- Task: Predict the most likely first transformation.\n- Required Justification: Compare bond dissociation energies (BDEs) and electronic factors at the candidate sites.\n- Constraint: Select the single best answer.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding:** The problem is firmly grounded in the principles of drug metabolism, a core topic in pharmacology and medicinal chemistry. It involves well-established enzyme families (Cytochrome P450s, Flavin-containing monooxygenases) found in human liver microsomes and their known catalytic mechanisms (C-H oxidation, N-oxidation, N-dealkylation). The use of bond dissociation energy (BDE) and electronic factors to predict regioselectivity of metabolic reactions is a standard and scientifically valid approach.\n- **Well-Posedness:** The problem provides a clear chemical scenario with two distinct, competing sites for metabolism: (1) the tertiary amine and its $\\alpha$-carbons, and (2) the remote isopropyl group. The qualifiers \"lipophilic,\" \"neutral,\" \"tertiary aliphatic,\" \"remote,\" and \"non-benzylic, non-allylic\" are precise and sufficient to allow for a reasoned comparison of reaction likelihoods based on established chemical principles. The question asks for the \"most likely\" outcome, which translates to a kinetic preference, a solvable problem.\n- **Objectivity:** The problem is stated using objective, technical language. There are no subjective or ambiguous terms.\n\nThe problem statement is internally consistent, scientifically sound, and well-posed. No flaws are identified.\n\n**Verdict:** The problem is valid.\n\n**Derivation of Solution**\n\nThe problem requires us to determine the most probable initial Phase I metabolic transformation of a drug molecule containing two potential sites for oxidation: a tertiary aliphatic amine and a remote, unactivated isopropyl group. The reaction is carried out in human liver microsomes, which are rich in Phase I oxidative enzymes, primarily the Cytochrome P450 (CYP) superfamily and the Flavin-containing Monooxygenase (FMO) family.\n\nWe must compare the relative reactivity of the different positions on the drug molecule towards these enzymes. The primary candidate sites for oxidation are:\n1.  The nitrogen atom of the tertiary amine (leading to N-oxidation).\n2.  The C-H bonds on the carbon atom(s) $\\alpha$ to the tertiary amine (leading to N-dealkylation).\n3.  The C-H bonds of the isopropyl group, specifically the tertiary (methine) C-H bond.\n\nLet's analyze the reactivity of these sites based on electronic factors and bond dissociation energies (BDEs).\n\n**Comparison of C-H Bond Reactivity for CYP-mediated Oxidation:**\nCYP-catalyzed oxidation of C-H bonds typically proceeds through a hydrogen atom transfer (HAT) mechanism. The rate of this step is inversely related to the strength of the C-H bond being broken, which is quantified by its BDE. A lower BDE corresponds to a weaker bond, a lower activation energy, and a faster reaction rate.\n\n-   **Site 3 (Isopropyl Group):** The isopropyl group is described as \"remote\" and attached to a \"saturated, non-benzylic, non-allylic carbon.\" This means it is electronically unactivated. The tertiary C-H bond at the methine position is the most likely site of attack within this group (tertiary C-H bonds are weaker than secondary or primary ones). The BDE of a tertiary C-H bond in a typical alkane is approximately $96.5 \\text{ kcal/mol}$.\n\n-   **Site 2 ($\\alpha$-Carbon to Amine):** The drug possesses a tertiary amine with at least one $\\alpha$-carbon bearing C-H bonds. A C-H bond positioned $\\alpha$ to a nitrogen atom is significantly weakened. This is due to the stabilizing effect of the adjacent nitrogen lone pair on the incipient carbon-centered radical formed after hydrogen abstraction. This resonance-like stabilization (or hyperconjugation) lowers the energy of the transition state. The BDE for a C-H bond $\\alpha$ to a tertiary amine is in the range of $85 - 90 \\text{ kcal/mol}$.\n\n**Kinetic Comparison:** The BDE of the C-H bond $\\alpha$ to the amine (ca. $85-90 \\text{ kcal/mol}$) is substantially lower than that of the tertiary C-H bond on the remote isopropyl group (ca. $96.5 \\text{ kcal/mol}$). This difference of $>6 \\text{ kcal/mol}$ translates to a large difference in reaction rates, making the hydrogen abstraction at the $\\alpha$-carbon to the nitrogen kinetically much more favorable. Therefore, CYP-mediated oxidation will preferentially occur at the position $\\alpha$ to the amine, rather than at the remote isopropyl group.\n\n**Mechanism following $\\alpha$-Carbon Oxidation:**\nWhen a CYP enzyme abstracts a hydrogen from the $\\alpha$-carbon, it generates an $\\alpha$-aminoalkyl radical. This rapidly recombines with the activated oxygen species of the CYP heme ($[\\text{Fe(IV)=O}]^{\\cdot+}$) to form a carbinolamine (or hemiaminal ether). A carbinolamine, having a hydroxyl group and an amine attached to the same carbon, is inherently unstable and spontaneously decomposes. This decomposition involves cleavage of the C-N bond, resulting in a secondary amine and a carbonyl compound (an aldehyde or ketone, depending on the substitution of the $\\alpha$-carbon). This entire sequence is termed **oxidative N-dealkylation**.\n\n**Comparison with Other Pathways:**\n-   **FMO-mediated N-oxidation (Site 1):** Tertiary amines are also excellent substrates for FMOs, which directly oxidize the nucleophilic nitrogen lone-pair to form a tertiary amine N-oxide. This is a competing pathway. The drug is described as \"lipophilic\" and \"overall neutral,\" which are favorable characteristics for FMO substrates. However, CYP-mediated N-dealkylation is an extremely facile and common pathway for tertiary amines that possess $\\alpha$-hydrogens, often dominating over N-oxidation. The prompt's emphasis on comparing BDEs as part of the justification lends weight to a mechanism initiated by C-H abstraction (N-dealkylation) over one initiated by direct heteroatom attack (N-oxidation).\n\n-   **Hydrolysis:** The direct hydrolytic cleavage of a stable C-N single bond in an aliphatic amine does not occur under physiological conditions and is not a recognized Phase I metabolic pathway.\n\n-   **Alcohol Dehydrogenase (ADH):** ADH enzymes oxidize alcohols. Since the starting material is not an alcohol, ADH cannot be responsible for the *initial* transformation.\n\n**Conclusion:** Based on the large difference in BDEs, the most reactive site on the molecule towards oxidative attack is the C-H bond on the carbon $\\alpha$ to the tertiary amine. The established mechanism for oxidation at this site by CYP enzymes is oxidative N-dealkylation, which proceeds through a carbinolamine intermediate. This pathway is kinetically favored over C-hydroxylation at the remote, unactivated isopropyl group. While FMO-mediated N-oxidation is plausible, CYP-mediated N-dealkylation is a highly probable, often dominant, pathway for such structures and is directly supported by the requested BDE analysis.\n\n**Option-by-Option Analysis**\n\n**A. Cytochrome P450 (CYP)-mediated oxidative N-dealkylation initiated by hydrogen abstraction at the carbon $\\alpha$ to the tertiary amine, proceeding through a carbinolamine that fragments to a secondary amine and a carbonyl compound.**\n-   **Analysis:** This option correctly identifies the most likely enzyme family (CYP), the most reactive site (carbon $\\alpha$ to the amine, due to electronic activation and low BDE), and the correct subsequent mechanistic steps (carbinolamine formation and fragmentation). This represents the kinetically favored pathway.\n-   **Verdict:** Correct.\n\n**B. Flavin-containing monooxygenase (FMO)-mediated N-oxidation of the tertiary amine to the corresponding amine N-oxide as the dominant initial pathway.**\n-   **Analysis:** This describes a plausible metabolic pathway. FMOs do oxidize tertiary amines to N-oxides. However, for a substrate with accessible $\\alpha$-hydrogens, CYP-mediated N-dealkylation is an extremely competitive and often dominant pathway. The BDE argument strongly favors a C-H abstraction mechanism like that in option A over direct N-oxidation. Thus, while possible, it is arguably not the *most* likely first transformation compared to the highly facile N-dealkylation pathway.\n-   **Verdict:** Incorrect.\n\n**C. Cytochrome P450 (CYP)-mediated hydroxylation at the methine carbon of the isopropyl group (the tertiary C–H) to yield a tertiary alcohol.**\n-   **Analysis:** As established by the BDE comparison, the C-H bond at this remote, unactivated position ($\\text{BDE} \\approx 96.5 \\text{ kcal/mol}$) is much stronger and less reactive than the C-H bond $\\alpha$ to the amine ($\\text{BDE} \\approx 85-90 \\text{ kcal/mol}$). Therefore, this pathway is kinetically disfavored and unlikely to be the primary metabolic route.\n-   **Verdict:** Incorrect.\n\n**D. Direct hydrolytic cleavage of a C–N bond of the tertiary amine to remove an alkyl group without prior oxidation.**\n-   **Analysis:** This is mechanistically incorrect. The C-N bond in a saturated aliphatic amine is robust and not susceptible to hydrolysis under physiological conditions. Cleavage requires prior oxidation to an unstable intermediate like a carbinolamine.\n-   **Verdict:** Incorrect.\n\n**E. Alcohol dehydrogenase-mediated oxidation of the isopropyl substituent to a ketone as the initiating step.**\n-   **Analysis:** Alcohol dehydrogenases (ADHs) require an alcohol as a substrate. The drug molecule as described has an alkyl (isopropyl) group, not an alcohol. ADH cannot perform the initial oxidation of an alkane. This cannot be the initiating step.\n-   **Verdict:** Incorrect.", "answer": "$$\\boxed{A}$$", "id": "4548577"}, {"introduction": "Many drugs can be metabolized at multiple sites, leading to a mixture of products. The distribution of these metabolites is not random; it is governed by the kinetics of each competing reaction pathway. This problem guides you through modeling such a scenario, demonstrating how the intrinsic clearance ($CL_{int}$) of each parallel pathway determines the fraction of the drug that is converted into a specific metabolite, especially at the low concentrations often found in the body. [@problem_id:4548421]", "problem": "A single oral dose of a parent drug undergoes Phase I oxidative biotransformation via two parallel and mutually exclusive pathways mediated by distinct cytochrome P450 (CYP) isoforms. Each pathway converts the same substrate to a different primary metabolite: pathway $1$ yields metabolite $M_1$, and pathway $2$ yields metabolite $M_2$. Assume classical Michaelis–Menten behavior for each pathway under steady-state conditions of the enzyme–substrate complex, mass-action kinetics, and negligible product inhibition or reverse reaction. Let the instantaneous formation rates of $M_1$ and $M_2$ be $v_1$ and $v_2$, respectively, and the total disappearance rate of the parent drug be $v_{\\text{tot}} = v_1 + v_2$. Define the fraction of metabolic flux to each metabolite as $f_i = v_i / v_{\\text{tot}}$ for $i \\in \\{1,2\\}$.\n\nIn the low-substrate limit where the substrate concentration $[S]$ is much smaller than the Michaelis constants of both pathways, the ratio $V_{\\max,i}/K_{m,i}$ for pathway $i$ is a well-tested descriptor of apparent catalytic efficiency that determines the proportionality of $v_i$ to $[S]$ in this regime. For the drug in question, experimental measurements establish $V_{\\max,1}/K_{m,1} = 5$ and $V_{\\max,2}/K_{m,2} = 2$ (in consistent units).\n\nStarting only from the stated kinetic assumptions and definitions, derive the expressions for $f_1$ and $f_2$ in the low-substrate limit and compute their numerical values using the provided $V_{\\max,i}/K_{m,i}$ ratios. Express your final answer as a single row matrix $\\begin{pmatrix} f_1 & f_2 \\end{pmatrix}$ with exact fractional values and no units. No rounding is required.", "solution": "The problem is validated as self-contained, scientifically grounded in established enzyme kinetics principles, and well-posed. All data and definitions required for a unique solution are provided, and there are no internal contradictions or scientifically unsound premises.\n\nThe kinetics of each of the two parallel biotransformation pathways are described by the Michaelis–Menten equation. For pathway $i$, where $i \\in \\{1, 2\\}$, the rate of formation of metabolite $M_i$, denoted by $v_i$, is given by:\n$$v_i = \\frac{V_{\\max,i} [S]}{K_{m,i} + [S]}$$\nHere, $[S]$ is the concentration of the parent drug (substrate), $V_{\\max,i}$ is the maximum reaction rate for pathway $i$, and $K_{m,i}$ is the Michaelis constant for pathway $i$.\n\nThe problem specifies that the analysis should be performed in the low-substrate limit, which is defined by the condition that the substrate concentration is much smaller than the Michaelis constants of both pathways: $[S] \\ll K_{m,1}$ and $[S] \\ll K_{m,2}$. Under this condition, the denominator of the Michaelis–Menten equation for each pathway can be approximated as follows:\n$$K_{m,i} + [S] \\approx K_{m,i}$$\nSubstituting this approximation into the rate equations, we obtain the expressions for $v_1$ and $v_2$ in the low-substrate regime:\n$$v_1 \\approx \\frac{V_{\\max,1} [S]}{K_{m,1}} = \\left(\\frac{V_{\\max,1}}{K_{m,1}}\\right) [S]$$\n$$v_2 \\approx \\frac{V_{\\max,2} [S]}{K_{m,2}} = \\left(\\frac{V_{\\max,2}}{K_{m,2}}\\right) [S]$$\nIn this limit, the reaction rates for both pathways are directly proportional to the substrate concentration $[S]$. The term $V_{\\max,i}/K_{m,i}$ is the intrinsic clearance ($CL_{\\text{int},i}$) of the pathway, which acts as the apparent first-order rate constant.\n\nThe total rate of disappearance of the parent drug, $v_{\\text{tot}}$, is the sum of the rates of the two parallel pathways:\n$$v_{\\text{tot}} = v_1 + v_2$$\nThe fraction of the total metabolic flux directed through pathway $i$, denoted by $f_i$, is defined as the ratio of the rate of that pathway to the total rate:\n$$f_i = \\frac{v_i}{v_{\\text{tot}}}$$\nWe can now derive the expression for $f_1$ by substituting the low-substrate approximations for $v_1$ and $v_2$:\n$$f_1 = \\frac{v_1}{v_1 + v_2} = \\frac{\\left(\\frac{V_{\\max,1}}{K_{m,1}}\\right) [S]}{\\left(\\frac{V_{\\max,1}}{K_{m,1}}\\right) [S] + \\left(\\frac{V_{\\max,2}}{K_{m,2}}\\right) [S]}$$\nAssuming a non-zero substrate concentration, $[S] \\neq 0$, the term $[S]$ cancels from the numerator and the denominator:\n$$f_1 = \\frac{\\frac{V_{\\max,1}}{K_{m,1}}}{\\frac{V_{\\max,1}}{K_{m,1}} + \\frac{V_{\\max,2}}{K_{m,2}}}$$\nSimilarly, the expression for $f_2$ is:\n$$f_2 = \\frac{v_2}{v_1 + v_2} = \\frac{\\left(\\frac{V_{\\max,2}}{K_{m,2}}\\right) [S]}{\\left(\\frac{V_{\\max,1}}{K_{m,1}}\\right) [S] + \\left(\\frac{V_{\\max,2}}{K_{m,2}}\\right) [S]} = \\frac{\\frac{V_{\\max,2}}{K_{m,2}}}{\\frac{V_{\\max,1}}{K_{m,1}} + \\frac{V_{\\max,2}}{K_{m,2}}}$$\nThese expressions show that in the low-substrate limit, the fractional flux through each pathway depends only on the ratio of the intrinsic clearances of the respective pathways, and not on the substrate concentration itself.\n\nThe problem provides the following numerical values for the intrinsic clearances:\n$$\\frac{V_{\\max,1}}{K_{m,1}} = 5$$\n$$\\frac{V_{\\max,2}}{K_{m,2}} = 2$$\nSubstituting these values into the derived expressions for $f_1$ and $f_2$:\n$$f_1 = \\frac{5}{5 + 2} = \\frac{5}{7}$$\n$$f_2 = \\frac{2}{5 + 2} = \\frac{2}{7}$$\nAs a check, the sum of the fractions is $f_1 + f_2 = \\frac{5}{7} + \\frac{2}{7} = \\frac{7}{7} = 1$, which is consistent with the definition of mutually exclusive and comprehensive pathways.\n\nThe final answer is to be expressed as a row matrix $\\begin{pmatrix} f_1 & f_2 \\end{pmatrix}$.", "answer": "$$\\boxed{\\begin{pmatrix} \\frac{5}{7} & \\frac{2}{7} \\end{pmatrix}}$$", "id": "4548421"}]}